The Taipei Municipal Wan Fang Hospital has advanced its thermal oncology center's capability by adding a superficial hyperthermia treatment room alongside the existing deep regional hyperthermia suite. MWFH, managed by Taipei Medical University, is a 732 beds facility located in Taipei, Taiwan, and the country's first publicly owned and privately operated hospital.
"Out of a broad field of competitors, the cancer treatment team recognized Pyrexar as the manufacturer of the best hyperthermia medical equipment in the world," according to Dennis Lin, CEO of Hualong Biomed. Wan Fang established its Hyperthermia Treatment Center in 2016, installing a BSD-2000 Deep Regional Hyperthermia system. Their team and patients have been looking forward to combining hyperthermia with radiotherapy and/or chemotherapy with the new BSD-500 Superficial Hyperthermia system, knowing that its odd ratio can be more than twice, especially for breast cancer and head and neck cancer patients.
In cooperation with Hematology-Oncology, Radiation Oncology, General Surgery, Otorhinolaryngology, and Oral Surgery departments, the Hyperthermia Treatment Center aims to benefit cancer patients, collect more clinical data and experience to promote this integrative cancer therapy. This is an important milestone in cancer treatment.
Special recognition to Ray Lauritzen, VP of CustomerCare at Pyrexar Medical. Ray arrived in Taiwan and was required to immediately enter the two-week quarantine for epidemic prevention before starting installation and training. Ray’s professionalism was formally recognized by the associate dean, professor, physician, nurses, medical physicists, radiation therapists, and case managers of the Cancer Treatment Center.